Stock 1672 ASCLETIS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 29/04/2024 BST 		5-day change 1st Jan Change
1.31 HKD -2.24% Intraday chart for Ascletis Pharma Inc. +3.15% -10.27%
04-03 Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus MT
04-03 Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ASCLETIS PHARMA INC. Stock Ascletis Pharma Inc.
-10.27% 173M -
CSL LIMITED Stock CSL Limited
-4.06% 86.13B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
A-
UCB Stock UCB
+56.46% 25.23B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.26% 15.36B
C
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
D+
INCYTE CORPORATION Stock Incyte Corporation
-16.72% 11.6B
B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.37% 8.71B
B+
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-7.02% 8.12B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1672 Stock
  4. Ratings Ascletis Pharma Inc.